TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:05
IRIDEX CORP ( IRIX ) https://www.iridex.com
2.51USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
IRIX
25.50%
SPY
32.74%
-64.55%
IRIX
SPY
92.93%
-44.96%
IRIX
SPY
224.41%
-70.75%
IRIX
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
41.55
36.47
0.05
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.25
0.76
3.44
-18.27
0.00
-5.56
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-13.14
43.74
-12.54
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.119
-23.21
-24.81
1.30
Other Earnings and Cash Flow Stats:
IRIDEX CORP ( IRIX ) Net Income TTM ($MM) is -6.76
IRIDEX CORP ( IRIX ) Operating Income TTM ($MM) is -7.14
IRIDEX CORP ( IRIX ) Owners' Earnings Annual ($MM) is -7.72
IRIDEX CORP ( IRIX ) Current Price to Owners' Earnings ratio is -5.28
IRIDEX CORP ( IRIX ) EBITDA TTM ($MM) is -4.95
IRIDEX CORP ( IRIX ) EBITDA Margin is -12.54%
Capital Allocation:
IRIDEX CORP ( IRIX ) has paid 0.00 dividends per share and bought back -0.293 million shares in the past 12 months
IRIDEX CORP ( IRIX ) has increased its debt by 1.127 million USD in the last 12 months
Capital Structure:
IRIDEX CORP ( IRIX ) Interest-bearing Debt ($MM) as of last quarter is 2
IRIDEX CORP ( IRIX ) Annual Working Capital Investments ($MM) are 2
IRIDEX CORP ( IRIX ) Book Value ($MM) as of last quarter is 12
IRIDEX CORP ( IRIX ) Debt/Capital as of last quarter is 24%
Other Balance Sheet Stats:
IRIDEX CORP ( IRIX ) has 7 million in cash on hand as of last quarter
IRIDEX CORP ( IRIX ) has 10 million of liabilities due within 12 months, and long term debt 0 as of last quarter
IRIDEX CORP ( IRIX ) has 16 common shares outstanding as of last quarter
IRIDEX CORP ( IRIX ) has 0 million USD of preferred stock value
Academic Scores:
IRIDEX CORP ( IRIX ) Altman Z-Score is -0.69 as of last quarter
IRIDEX CORP ( IRIX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
IRIDEX CORP ( IRIX ) largest shareholder is Bank of New York Mellon Corp owning 34693 shares at 0.09 ($MM) value
Nandini Devi(an insider) Bought 2000 shares of IRIDEX CORP ( IRIX ) for the amount of $6200.00 on 2022-05-20
25.38% of IRIDEX CORP ( IRIX ) is held by insiders, and 23.24% is held by institutions
IRIDEX CORP ( IRIX ) went public on 1996-02-15
Other IRIDEX CORP ( IRIX ) financial metrics:
FCF:-7.68
Unlevered Free Cash Flow:-9.78
EPS:-0.43
Operating Margin:-13.14
Gross Profit Margin:43.74
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-58.16
Beta:1.30
Buffet's Owners Earnings:-7.72
Price to Owner's Earnings:-5.28
About IRIDEX CORP ( IRIX ) :
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.